SA520412443B1 - تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول - Google Patents
تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازولInfo
- Publication number
- SA520412443B1 SA520412443B1 SA520412443A SA520412443A SA520412443B1 SA 520412443 B1 SA520412443 B1 SA 520412443B1 SA 520412443 A SA520412443 A SA 520412443A SA 520412443 A SA520412443 A SA 520412443A SA 520412443 B1 SA520412443 B1 SA 520412443B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- once daily
- daily administration
- ophthalmic compositions
- benzimidazole compounds
- compositions once
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382021 | 2018-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA520412443B1 true SA520412443B1 (ar) | 2022-09-01 |
Family
ID=61017875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA520412443A SA520412443B1 (ar) | 2018-01-18 | 2020-07-15 | تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول |
Country Status (28)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025508704A (ja) * | 2022-02-17 | 2025-04-10 | ファエス・ファルマ・ソシエダッド・アノニマ | １日１回非経口投与のためのビラスチン組成物 |
| CN116211795B (zh) * | 2022-12-26 | 2025-09-26 | 深圳市贝美药业有限公司 | 一种比拉斯汀口服液体制剂及其制备方法 |
| CN115970066B (zh) * | 2022-12-29 | 2024-09-27 | 成都爱睿康乐医疗器械有限公司 | 基于主客体相互作用的载药纳米凝胶生物润滑剂及其制备方法和应用 |
| WO2024224326A1 (en) * | 2023-04-27 | 2024-10-31 | Leiutis Pharmaceuticals Llp | Liquid parenteral formulations of bilastine |
| WO2024224308A1 (en) * | 2023-04-27 | 2024-10-31 | Leiutis Pharmaceuticals Llp | Liquid parenteral formulations of bilastine free of cyclodextrins |
| WO2024256956A1 (en) * | 2023-06-13 | 2024-12-19 | Leiutis Pharmaceuticals Llp | Stable formulations of bilastine for nasal and ophthalmic use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1229075B (it) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| ES2048109B1 (es) | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| JP3527256B2 (ja) | 1992-12-09 | 2004-05-17 | ロート製薬株式会社 | 抗アレルギー点眼剤 |
| TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
| ES2124167B1 (es) | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| CA2484460C (en) | 2002-04-19 | 2009-09-29 | Faes Farma, S.A. | Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-yl]-1-piperidinyl]ethyl]-.alpha..alpha. dimethyl-benzeneacetic acid |
| US20050239745A1 (en) * | 2004-03-03 | 2005-10-27 | Ophthalmic Research Associates, Inc. | Novel topical ophthalmic formulations |
| US7247623B2 (en) | 2005-08-19 | 2007-07-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with non-drying antihistamines |
| WO2007047253A2 (en) | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| UA94938C2 (ru) * | 2006-03-31 | 2011-06-25 | ВИСТЕКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи | Офтальмическая композиция для лечения клинических симптомов глазной аллергии, которая содержит алкафтадин или его производное (варианты) |
| SG170044A1 (en) * | 2006-03-31 | 2011-04-29 | Vistakon Pharmaceuticals Llc | Ocular allergy treatments |
| JP2010531898A (ja) | 2007-06-28 | 2010-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | 鼻および眼へのコルチコステロイド水溶液送達 |
| JP2012520880A (ja) * | 2009-03-17 | 2012-09-10 | アーシエックス セラピューティックス， インコーポレイテッド | ケトチフェンの眼科用製剤および使用方法 |
| TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物 |
| CN103110575B (zh) * | 2013-03-07 | 2014-11-05 | 宁夏康亚药业有限公司 | 一种美洛昔康滴眼液及其制备方法和应用 |
| WO2014150899A1 (en) * | 2013-03-15 | 2014-09-25 | Chapin Matthew J | Topical ophthalmic formulations for treating migraine |
| CN103784462A (zh) * | 2014-02-25 | 2014-05-14 | 宋俊智 | 包含比拉斯汀及甾族化合物的药物制剂 |
| EP3040334A1 (en) | 2014-12-29 | 2016-07-06 | Faes Farma, S.A. | New benzimidazole derivatives as antihistamine agents |
-
2019
- 2019-01-09 EA EA202091725A patent/EA202091725A1/ru unknown
- 2019-01-09 DK DK19701154.7T patent/DK3740191T3/da active
- 2019-01-09 ES ES19701154T patent/ES2878107T3/es active Active
- 2019-01-09 CA CA3088740A patent/CA3088740A1/en not_active Abandoned
- 2019-01-09 MA MA51612A patent/MA51612B1/fr unknown
- 2019-01-09 SI SI201930076T patent/SI3740191T1/sl unknown
- 2019-01-09 EP EP19701154.7A patent/EP3740191B1/en active Active
- 2019-01-09 HR HRP20211037TT patent/HRP20211037T1/hr unknown
- 2019-01-09 HU HUE19701154A patent/HUE054594T2/hu unknown
- 2019-01-09 JP JP2020539288A patent/JP7309729B2/ja active Active
- 2019-01-09 KR KR1020207023573A patent/KR102695627B1/ko active Active
- 2019-01-09 LT LTEP19701154.7T patent/LT3740191T/lt unknown
- 2019-01-09 MX MX2020007692A patent/MX2020007692A/es unknown
- 2019-01-09 PT PT197011547T patent/PT3740191T/pt unknown
- 2019-01-09 CN CN201980009293.0A patent/CN111727035B/zh active Active
- 2019-01-09 US US16/963,219 patent/US20210128544A1/en not_active Abandoned
- 2019-01-09 EP EP21169956.6A patent/EP3915539A1/en not_active Withdrawn
- 2019-01-09 AU AU2019209214A patent/AU2019209214B2/en active Active
- 2019-01-09 PL PL19701154T patent/PL3740191T3/pl unknown
- 2019-01-09 WO PCT/EP2019/050433 patent/WO2019141563A1/en not_active Ceased
- 2019-01-17 PY PY201901903392A patent/PY1903392A/es unknown
- 2019-01-17 AR ARP190100094A patent/AR114216A1/es not_active Application Discontinuation
- 2019-01-17 TW TW108101861A patent/TWI833727B/zh active
- 2019-01-18 UY UY38055A patent/UY38055A/es not_active Application Discontinuation
-
2020
- 2020-07-15 SA SA520412443A patent/SA520412443B1/ar unknown
- 2020-07-17 CL CL2020001895A patent/CL2020001895A1/es unknown
- 2020-08-13 CO CONC2020/0009992A patent/CO2020009992A2/es unknown
- 2020-08-17 ZA ZA2020/05077A patent/ZA202005077B/en unknown
-
2021
- 2021-06-25 CY CY20211100569T patent/CY1124270T1/el unknown
-
2025
- 2025-10-02 US US19/347,880 patent/US20260027099A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091725A1 (ru) | Офтальмические композиции, содержащие биластин, бета-циклодекстрин и по крайней мере одно желатинирующее вещество | |
| MX2021004431A (es) | Procesos novedosos. | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| CR20220105A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| MX2020011196A (es) | Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida. | |
| PH12021552760A1 (en) | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| MX2020001403A (es) | Nuevos derivados de quinolina. | |
| PH12022551359A1 (en) | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| EA202090029A1 (ru) | Твердая композиция карипразина для орального введения | |
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| PH12022551177A1 (en) | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| ZA202308388B (en) | Nasal compositions comprising alcaftadine | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| MX2021012684A (es) | Composiciones farmaceuticas estables y conservadas de bilastina. | |
| EA201992826A1 (ru) | 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ | |
| MX2009007038A (es) | Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales. | |
| EA202090965A1 (ru) | Водные композиции биластина | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine |